Taking Stock of the Country's Pharma Sector

Total Page:16

File Type:pdf, Size:1020Kb

Taking Stock of the Country's Pharma Sector STATSGURU: Taking stock of the country’s pharma sector THE INDIAN pharma sector has been shaken up by the than domestic firms. Meanwhile, pharma exports have grown large, most companies that are doing well have similar price-earnings sale of Ranbaxy Laboratories to Sun Pharmaceutical steadily over the past few years, as Table 2 shows. multiples, above 20, as demonstrated by Table 4. And the BSE’s pharma Industries by Ranbaxy’s erstwhile Japanese owners, What is also worth noting is that, for some companies like Sun index has shown a steady increase, clearly visible in Table 5 – at less Daiichi Sankyo. Pharma and Wockhardt, earnings from abroad have come to occupy a volatility than the Sensex. However, as Table 6 shows, several companies The sector, overall, has posted reasonable operating profits, as much larger segment of revenue than they did earlier, as Table 3 shows. — such as Ranbaxy, of course, as also Jubilant and Cadila — had periods Table 1 shows – but multinationals have seen much greater volatility How is the market reacting to changes in the pharma sector? By and last year in which their stock prices were under severe stress. 1: MNC FIRMS SAW MORE VOLATILITY THAN INDIAN ONES... 2: ...WHILE EXPORTS GREW IN THE PAST FEW YEARS Operating profit margin (% of net sales) Value of pharma exports* ($ mn) Source: Capitaline * Drugs,pharmaceuticals and fine chemicals Source: DGCIS, Kolkata 3: FOR SOME FIRMS, EARNINGS FROM ABROAD NOW MAKE UP A CHUNK OF THEIR REVENUE 4: MOST FIRMS DOING WELL HAVE SIMILAR P-Es Revenue earnings in forex (as % of total revenue) Price-to-earnings multiples (X) BSE Sun Pharma Lupin Cadila Cipla Glenmark Aurobindo Dr Reddy’s Wockhardt Ranbaxy Jubilant Healthcare Inds Health Pharma Pharma Labs Labs Life *According to standalone data Source: Capitaline Base on TTM EPS as on April 10, 2014 Source: Capitaline 5:BSE’S PHARMA INDEX HAS SHOWN A STEADY RISE 6: STOCKS OF SOME FIRMS HAVE SEEN AN UPTICK, WHILE OTHERS HAVE COME UNDER SEVERE STRESS, IN THE PAST YEAR BSE Heatlthcare vs Sensex Share price on BSE (in ~) Ranbaxy Laboratories Dr. Reddy’s Laboratories Sun Pharmaceutical Industries Lupin Cipla Cadila Healthcare Aurobindo Pharma Wockhardt Jubilant Life Sciences Glenmark Pharmaceuticals Source: Bloomberg Source: BSE StatsGuru is a weekly feature. Every Monday, Business Standard guides you through the numbers you need to know to make sense of the headlines Compiled by BS Research Bureau.
Recommended publications
  • 50 KW Offer Solar Copy 2
    21st Century Enviro Engineers Pvt.Ltd. Plot No. 120(10 Marla), COMPANY Industrial Area Phase II Chandigarh - 160002, India PROFILE www.21stcenturyenviro.com INTRODUCTION 21st CENTURY ENVIRO ENGINEERS PVT. LTD. is a Company dealing in the field of Environmental Engineering related activities. We are Registered Environmental Consultants of Pollution Control Board to Supply ETP’s, STP’s, APCD’s, Incinerators, Water Treatment Plants, Reverse Osmosis, Evaporators, Solid Waste Management and Rain Water Harvesting and to carry out EIA Studies . The Directors of the company are young Technocrats having versatile experience in this field. We have a back up of highly qualified and experienced technical team having versatile experience in Designing, Erection, Commissioning and Operation of different types of Effluent Treatment Plants. Our Managing Director himself is a Chemical Engineer with almost 25 Years Experience in this line and Technical Director is PhD. in Environmental Science with almost 30 Years working experience on various types of effluent treatment Technologies. Our team comprises of almost 150 people from different backgrounds e.g. Chemical, Environmental, Mechanical, Instrumentation, Civil, Accounts, Purchase, Marketing etc. We have our Marketing/ Design Office in Chandigarh and regional offices in Dhaka, Mumbai, New Delhi, Sikkim etc. and have our own testing Laboratory for Effluent/Water Testing and to study treatability of effluent on pilot scale. We have our own full-fledged manufacturing unit of Pollution Control Equipments in Village Kunjhal Baddi (HP). We also undertake annual operation and maintenance contracts and liasining services for the systems supplied by us. We are also Registered with CREST (Chandigarh Renewable Energy & Technology Promotion Society) and SECI (Solar Energy Corporation of India) for supplying Online/Offline Solar systems in Chandigarh, Himachal Pradesh, Uttarakhand, J&K, Punjab, Haryana, Delhi, Bihar etc.
    [Show full text]
  • Glenmark Pharmaceuticals (GLEPHA)
    Glenmark Pharmaceuticals (GLEPHA) CMP: | 483 Target: | 560 (16%) Target Period: 12 months BUY August 17, 2020 Subdued topline; margin expansion to the fore… Revenues stayed flattish growing just 0.9% YoY to | 2345 crore due to subdued growth of 1.6% in US to | 743 crore, 3.7% growth in domestic sales to | 780 crore. Europe business grew 12.8% YoY to | 274 crore. RoW markets de-grew 18.1% YoY to 212 crore. EBITDA margins improved 567 bps YoY to 20.4% mainly due to lower other expenditure. EBITDA grew Particulars 39.8% YoY to | 478 crore. Adjusted PAT grew 106.9% YoY to | 226 crore. P articular Am ount Delta vis-à-vis EBITDA was due to higher other income. Exceptional items in Market Capitalisation | 13615 crore Q1FY21 were | 28 crore on gain arising from sale of Vwash brand to HUL. Debt (FY20) | 4868 crore Result Update Result Cash & equivalent (FY20) | 1111 crore US growth dependent on new launches E V | 17371 crore 52 week H/L (|) 573/168 US generics comprise ~30% of total revenues. So far, the company has E quity capital | 28.2 crore Face value | 1 received approval for 164 ANDAs while another 44 are pending approval, of which 24 are Para IV applications. However, Glenmark’s derma portfolio is Key Highlights facing stiff pricing pressure in the US. Going ahead, traction from the newly commissioned US based Monroe facility will be the key determinant besides Q1FY21 revenues remained flattish sustained product launches. We expect the US to grow at 5.2% CAGR in due to subdued US growth amid FY20-22E to | 3479 crore on the back of new launches.
    [Show full text]
  • Hy Sun Missed the Pharma Rally: the Answer Is Hidden in a Bet Many Failed — Speciality Drugs - the Economic Times
    12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets News Industry RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More Aayush English Edition | E-Paper Tech Consumer Markets Corporate Governance Telecom + OTT Auto + Aviation Pharma Fintech + BFSI Economy Infra Environment Energy Business News › Prime › Pharma › Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Getty Images MARKETS hy Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Dilip Shanghvi, founder and managing director, Sun Pharmaceuticals Synopsis Sun Pharma is the only Indian company to have made some inroads into speciality drugs. What worries investors is high investments and uncertainties over ramp up in revenue. The stock can still see upside because of its current valuations, strong India business, and any positive surprises in US generic business. But it is crucial that its speciality bet pays off. BACK TO TOP https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-sun-missed-the-pharma-rally-the-answer-is-hidden-in-a-bet-many-failed-spe… 1/11 12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets NeCwasllI nitd uas trbyleRssISiEngP oilniti cdsisWgeuailthse fMoFr tTheceh InJodbisanOpinion NRI Panache ET NOW More pharmaceutical industry. The stocks of pharma companies have been on a tear since the beginning of the Covid-19 crisis.
    [Show full text]
  • DIA India ICH Day 2019 Enhancing Clinical Trial Outcomes with ICH 30Th August, 2019 | Taj Lands End | Mumbai, India
    DIA India ICH Day 2019 Enhancing Clinical Trial Outcomes with ICH 30th August, 2019 | Taj Lands End | Mumbai, India PROGRAMME COMMITTEE Today, the Indian pharmaceutical industry supplies approximately 20% of the world’s generic drugs and has the largest number of FDA-approved manufacturing facilities C. Michelle Limoli outside of the US. This industry has evolved during the past decade into innovative drug Senior International development, including new chemical and biological entities, biosimilars, and innovative Health Science Advisor differentiated products. At the same time, as healthcare costs continue to rise across the US FDA world, so does the global need for affordable, innovative healthcare. Against this backdrop, DIA India aims to create an initiative that will address the clinical and regulatory aspects Ramesh Jagannathan of drug development, through a comprehensive single day workshop on the latest ICH Associate Vice President guidelines and developments relevant for India. - R&D Biocon Ltd. Objective Anupama Ramkumar CEO and Principal The objective of this program is to provide a common platform for ICH trainers, regulatory Consultant authorities, academia, investigators, service providers, and the Indian biopharmaceutical Arkus Research Pvt. Ltd. industry, to deliberate upon and understand ICH guidelines and the most recent updates, impacting the drug development spectrum including key clinical, regulatory and quality Seema Pai aspects. Director - India Cluster Global Site & Study Take a look at our key topics for the event
    [Show full text]
  • Loan Against Securities – Approved Single Scrips
    Loan against securities – Approved Single Scrips SR no ISIN Scrip Name Margin 1 INE216A01030 BRITANNIA INDUSTRIES LIMITED 50 2 INE854D01024 UNITED SPIRITS LIMITED 50 3 INE437A01024 APOLLO HOSPITALS ENTERPRISE LTD 50 4 INE208A01029 ASHOK LEYLAND LTD 50 5 INE021A01026 ASIAN PAINTS LTD 50 6 INE406A01037 AUROBINDO PHARMA LTD 50 7 INE917I01010 BAJAJ AUTO LTD 50 8 INE028A01039 BANK OF BARODA 50 9 INE084A01016 BANK OF INDIA 50 10 INE463A01038 BERGER PAINTS INDIA LTD 50 11 INE029A01011 BHARAT PETROLEUM CORPORATION LTD 50 12 INE323A01026 BOSCH LTD 50 13 INE010B01027 CADILA HEALTHCARE LTD 50 14 INE059A01026 CIPLA LTD 50 15 INE522F01014 COAL INDIA LTD 50 16 INE259A01022 COLGATE-PALMOLIVE (INDIA) LTD 50 17 INE361B01024 DIVIS LABORATORIES LTD 50 18 INE089A01023 DRREDDYS LABORATORIES LTD 50 19 INE129A01019 GAIL (INDIA) LTD 50 20 INE860A01027 HCL TECHNOLOGIES LTD 50 21 INE158A01026 HERO MOTOCORP LTD 50 22 INE038A01020 HINDALCO INDUSTRIES LTD 50 23 INE094A01015 HINDUSTAN PETROLEUM CORPORATION LTD 50 24 INE030A01027 HINDUSTAN UNILEVER LTD 50 25 INE079A01024 AMBUJA CEMENTS LTD 50 26 INE001A01036 HOUSING DEVELOPMENT FINANCE CORPLTD 50 27 INE090A01021 ICICI BANK LTD 50 28 INE242A01010 INDIAN OIL CORPORATION LTD 50 29 INE009A01021 INFOSYS LTD 50 30 INE154A01025 ITC LTD 50 31 INE237A01028 KOTAK MAHINDRA BANK LTD 50 32 INE498L01015 LT FINANCE HOLDINGS LTD 50 33 INE018A01030 LARSEN TOUBRO LTD 50 34 INE326A01037 LUPIN LTD 50 35 INE101A01026 MAHINDRA MAHINDRA LTD 50 36 INE585B01010 MARUTI SUZUKI INDIA LTD 50 37 INE775A01035 MOTHERSON SUMI SYSTEMS LTD 50 38 INE883A01011
    [Show full text]
  • Franklin India Fund LU1212701376 31 August 2021
    Franklin Templeton Investment Funds India Equity Franklin India Fund LU1212701376 31 August 2021 Fund Fact Sheet For Professional Client Use Only. Not for distribution to Retail Clients. Fund Overview Performance Base Currency for Fund USD Performance over 5 Years in Share Class Currency (%) Total Net Assets (USD) 1,44 billion Franklin India Fund A (acc) EUR-H1 MSCI India Index-NR in USD Fund Inception Date 25.10.2005 190 Number of Issuers 45 170 Benchmark MSCI India Index-NR 150 Morningstar Category™ Other Equity 130 Summary of Investment Objective The Fund aims to achieve long-term capital appreciation by 110 principally investing in equity securities of companies of any size located or performing business predominately in India. 90 Fund Management 70 Sukumar Rajah: Singapore 50 08/16 02/17 08/17 02/18 08/18 02/19 08/19 02/20 08/20 02/21 08/21 Asset Allocation Discrete Annual Performance in Share Class Currency (%) 08/20 08/19 08/18 08/17 08/16 08/21 08/20 08/19 08/18 08/17 A (acc) EUR-H1 50,51 -1,01 -13,58 -3,55 9,44 Benchmark in USD 53,15 3,00 -7,64 7,12 17,46 % Performance in Share Class Currency (%) Equity 103,05 Cumulative Annualised Cash & Cash Equivalents -3,05 Since Since 1 Mth 3 Mths 6 Mths 1 Yr 3 Yrs 5 Yrs Incept 3 Yrs 5 Yrs Incept A (acc) EUR-H1 7,78 9,87 19,92 50,51 28,75 35,90 46,91 8,79 6,33 6,24 Benchmark in USD 10,94 11,12 22,35 53,15 45,68 83,30 84,41 13,36 12,89 10,11 Calendar Year Performance in Share Class Currency (%) 2020 2019 2018 2017 2016 A (acc) EUR-H1 9,54 4,01 -17,74 34,53 0,74 Benchmark in USD 15,55 7,58 -7,31 38,76 -1,43 Past performance is not an indicator or a guarantee of future performance.
    [Show full text]
  • (15) Sr No Student Name Program Graduated
    5.2.2 Average percentage of placement of outgoing students during the last five years (15) Package in Download Sr No Student Name Program graduated from Name of Employer Lac. Proof 1 Yash Kothari B. Tech (Computer Science and Engineering) Media.net 2995000 Click Here 2 Chavda Vijay Ganpatbhai B. Tech (Computer Science and Engineering) eInfochip 450000 Click Here 3 Shah Shikha Snehal B. Tech (Computer Science and Engineering) Endurance International Group 1400000 Click Here 4 Darshan Kanubhai Darji B. Tech (Computer Science and Engineering) Blue Optima Limited 700000 Click Here 5 Jaydutt Nareshbhai Patel B. Tech (Computer Science and Engineering) Samsung R&D Bangalore 1300000 Click Here 6 Kamiyabali Shabbirali Dedhrotia B. Tech (Computer Science and Engineering) Amazon 2875000 Click Here 7 Rutvik Kartik Sutaria B. Tech (Computer Science and Engineering) Amazon 2875000 Click Here 8 Yash Rasikbhai Sinojiya B. Tech (Computer Science and Engineering) Amazon 2875000 Click Here 9 Khushboo Sanjay Shah B. Tech (Computer Science and Engineering) Deutsche Bank 1430000 Click Here 10 Priyanka Deepak Jiandani B. Tech (Computer Science and Engineering) Deutsche Bank 1430000 Click Here 11 Devam Manish Doshi B. Tech (Computer Science and Engineering) Endurance International Group 1400000 Click Here 12 Bhavan Manoj Prajapati B. Tech (Computer Science and Engineering) Samsung R&D Bangalore 1300000 Click Here 13 Het Shaileshbhai Pandya B. Tech (Computer Science and Engineering) Samsung R&D Bangalore 1300000 Click Here 14 Azhar Ali Khaked B. Tech (Computer Science and Engineering) Canary Mail 1220000 Click Here 15 Dhanin Satish Gupta B. Tech (Computer Science and Engineering) Samsung R&D 1200000 Click Here 16 Haridutt Prakashbhai Jani B.
    [Show full text]
  • Company Reliance Industries Limited Tata Consultancy Services
    Top 1000 Private Sector Companies (Rank-wise List) Company Reliance Industries Limited Tata Consultancy Services (TCS) Infosys Technologies Ltd Wipro Limited Bharti Tele-Ventures Limited ITC Limited Hindustan Lever Limited ICICI Bank Limited Housing Development Finance Corp. Ltd. TATA Steel Limited Ranbaxy Laboratories Limited HDFC Bank Ltd Tata Motors Limited Larsen & Toubro Limited (L&T) Satyam Computer Services Ltd. Maruti Udyog Limited Bajaj Auto Ltd. HCL Technologies Ltd. Hero Honda Motors Limited Hindalco Industries Ltd Reliance Energy Limited Grasim Industries Limited Jet Airways (India) Ltd. Sun Pharmaceuticals Industries Ltd Cipla Ltd. Gujarat Ambuja Cements Ltd. Videsh Sanchar Nigam Limited The Tata Power Company Limited Sterlite Industries (India) Ltd. Associated Cement Companies Ltd. Nestlé India Ltd. Hindustan Zinc Limited GlaxoSmithKline Pharmaceuticals Limited Siemens India Ltd. Motor Industries Company Limited Mahindra & Mahindra Limited UTI Bank Ltd. Zee Telefilms Limited Bharat Forge Limited ABB Limited i-Flex Solutions Ltd. Dr. Reddy's Laboratories Ltd. Nicholas Piramal India Limited Kotak Mahindra Bank Limited Reliance Capital Ltd. Ultra Tech Cement Ltd. Patni Computer Systems Ltd. Wockhardt Limited Indian Petrochemicals Corporation Limited Biocon India Limited Essar Oil Limited. Asian Paints Ltd. Dabur India Limited Jaiprakash Associates Limited JSW Steel Limited Tata Chemicals Limited Tata Tea Limited Tata Teleservices (Maharashtra) Limited The Indian Hotels Co. Ltd. Glenmark Pharmaceuticals Limited NIRMA Limited Jindal Steel & Power Ltd HCL Infosystems Ltd. Cadila Healthcare Limited Colgate-Palmolive (India) Limited The Great Eastern Shipping Company Limited Aventis Pharma India Ltd Ashok Leyland Limited Pantaloon Retail (India) Limited Indian Rayon And Industries Limited Financial Technologies (India) Ltd United Phosphorus Limited Matrix Laboratories Limited Sesa Goa Limited Lupin Ltd Cummins India Limited Crompton Greaves Limited.
    [Show full text]
  • Final Placement Report 2020-21
    FINAL PLACEMENT REPORT POST GRADUATE ProgrAM IN MANAGEMENT (PGP) 2019-21 12th BAtcH INDIAN INSTITUTE OF MANAGEMENT SHILLONG FOREWORD The Placement Committee of IIM Shillong takes immense pride in announcing the successful completion of the final placement season for the PGP batch of 2019-21. The stellar performance by the PGP participants stands testimony to the rapid progress made by IIM Shillong and has once again established IIM Shillong as the preferred choice for recruiters. We express our gratitude to our regular recruiters who have continuously believed in the mettle of our students and have furthered their association with us for another year to facilitate this mutually beneficial relationship. We are also grateful to our new recruiters, who have acknowledged the potential of our students and provided them with a plethora of opportunities. We appreciate the contribution of the entire IIM Shillong fraternity for their sustained assistance in the placement process. With continued support from students, recruiters, faculty, alumni, staff and management, we hope to carry this momentum onto the next academic year. Prof. Rohit Joshi Chairperson Placement Committee IIM Shillong BATCH PROFILE OF 2019-21 Education Background 9% 9% 9% 57% 198 16% Number 61% 39% of Students Male Female Engineering Arts Commerce & Finance Others Science Work Experience by Months Domain wise Work Experience Freshers 27% Information Technology & Analytics 47% 01-12 months 23% Consulting & Strategy 13% 19% Finance 23% 13-24 months 18% Sales & Marketing 11% 25-36
    [Show full text]
  • Stocks to Watch: Dish TV, Eicher, M&M
    Stocks to Watch: Dish TV, Eicher, M&M, Metropolis Health, Sun Pharma Friday, May 28, 2021 - Morning brief for the stock market: TOP EVENTS TODAY * Nifty 50 company detailing Jan-Mar earning: + Mahindra & Mahindra and Mahindra Vehicle Manufacturers, (Net profit seen 10.97 bln rupees vs 32.6 bln rupees loss year ago) * Jan-Mar earnings to be detailed by: 3M India, Incon Engineers, Rolcon Engineering Co, Action Construction Equipment, India Nippon Electricals, RSWM, AD Manum Finance, Indian Bank, Servoteach Industries, Aditya Birla Fashion and Retail, Indokem, Sharp Investments, Ador Multiproducts, IPCA Laboratories, Shish Industries, Ador Welding, ITD Cementation India, Shree Rama Newsprint, 1 Arvind Smartspaces, Jagran Prakashan, Shree Steel Wire Ropes, Associated Alcohols & Breweries, Jindal Poly Films, Shree Tulsi Online.Com, Aurionpro Solutions, Kama Holdings, Si Capital & Financial Services, Batliboi, Kanoria Chemicals & Industries, Sikozy Realtors, Bengal & Assam Co, Karur Vysya Bank, Sirca Paints India, Kovilpatti Lakshmi Roller Flour Blue Circle Services, SMS Pharmaceuticals, Mills, Lakshmi Electrical Control Bridge Securities, SRG Housing Finance, Systems, Calcom Vision, Max Healthcare Institute, SRU Steels, Camlin Fine Sciences, Mindteck India, Stanpacks India, Central Bank of India, Munoth Communication, Steel Exchange India, Chemo Pharma Laboratories, Munoth Financial Services, Steelcast, City Union Bank, NACL Industries, Sudal Industries, Classic Filaments, Navkar Corp, Sudarshan Chemical Industries, Confidence Futuristic Energetech,
    [Show full text]
  • In the United States District Court for the District of Delaware
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE NOVARTIS PHARMACEUTICALS CORPORATION Plaintiff, v. Civil Action No. _____ APOTEX INC., APOTEX CORP., BIONPHARMA INC., EMCURE PHARMACEUTICALS, HERITAGE PHARMACEUTICALS INC., EZRA VENTURES, LLC, GLENMARK PHARMACEUTICALS INC., USA, GLENMARK PHARMACEUTICALS LIMITED, HEC PHARM CO., LTD., HEC PHARM USA INC., HETERO USA INC., HETERO LABS LIMITED UNIT-V, HETERO LABS LIMITED, PRINSTON PHARMACEUTICAL INC., STRIDES GLOBAL PHARMA PRIVATE LIMITED, STRIDES PHARMA, INC., ZYDUS PHARMACEUTICALS (USA) INC., and CADILA HEALTHCARE LIMITED Defendants. COMPLAINT Novartis Pharmaceuticals Corporation (“Novartis”) by its attorneys hereby alleges as follows: NATURE OF THE ACTION 1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code and for declaratory judgment pursuant to the Declaratory Judgment Act, 28 U.S.C. §§ 2201, et seq . This action relates to Abbreviated New Drug Applications (“ANDAs”) filed by the above-named defendants with the U.S. Food and Drug Administration (“FDA”) for approval to engage in the commercial manufacture, use, or sale of Fingolimod 0.5 mg capsules, generic versions of Novartis’s GILENYA ® Capsules, 0.5 mg, prior to expiration of U.S. Patent No. 10,543,179 (“the ’179 patent”). ME1 32500579v.1 PARTIES A. Novartis 2. Novartis Pharmaceuticals Corporation is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business in East Hanover, New Jersey. B. The Generic Defendants a) Apotex Inc.; Apotex Corp. 3. Upon information and belief, Defendant Apotex Inc. is a corporation organized and existing under the laws of Canada, having a principal place of business at 150 Signet Drive, Toronto, Ontario, Canada M9L 1T9.
    [Show full text]
  • Cipla Limited
    Cipla Limited Registered Office: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013 Phone: (9122) 2482 6000, Fax: (9122) 2482 6893, Email: [email protected], Website: www.cipla.com Corporate Identity Number: L24239MH1935PLC002380 Annexure to the Board’s Report Particulars of employee remuneration for the financial year ended 31st March, 2017 As required under section 197(12) of the Companies Act, 2013, read with rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. Employed throughout the year Name Designation Qualification Experience Age Date of Last employment Remuneration (in years) (in years) Employment (`) Abhayan Jawaharlal CLO - International B.Com, LLB 18 45 03-09-2012 Biocon Group 12,009,351 Ajay Luharuka Head - IPD and API Finance B.Com, MMS, CFA 21 44 11-07-1996 NIIT Limited 12,800,997 Anil Kumar Kartha Site Head - Patalganga B. Sc., B. Pharm 26 54 27-05-1991 Vysali Pharmaceuticals 12,779,636 Anita S Desai Head - Formulations ADL B. Sc., PGCT 22 49 18-07-1994 Bombay Drug House 11,775,986 Anuj Aggarwal Regional Head - EU B. Tech., MBA 13 35 08-07-2013 Mckinsey & Company 13,664,962 Anupam Kashiv Head - Shared Services MPBSE 27 51 18-11-2013 Cadbury Business Services 27,837,834 Balwinder Singh Sethi Regional Head – MENA M.A 19 52 09-01-2012 Promed Exports Pvt Ltd 15,543,864 Chandru Chawla Global Head - CNV, Strategy and B. Tech., PG 29 51 12-12-2011 Lupin Limited 33,920,416 M&A Debashis Sarkar Head - Marketing and APAC DTM B.
    [Show full text]